{"id":"https://openalex.org/W4313178477","doi":"https://doi.org/10.1183/13993003.congress-2022.3599","title":"Recombinant AAT-Fc fusion protein INBRX-101 achieves normal serum AAT levels in patients with alpha-1 antitrypsin deficiency (AATD)","display_name":"Recombinant AAT-Fc fusion protein INBRX-101 achieves normal serum AAT levels in patients with alpha-1 antitrypsin deficiency (AATD)","publication_year":2022,"publication_date":"2022-09-04","ids":{"openalex":"https://openalex.org/W4313178477","doi":"https://doi.org/10.1183/13993003.congress-2022.3599"},"language":"en","primary_location":{"id":"doi:10.1183/13993003.congress-2022.3599","doi":"https://doi.org/10.1183/13993003.congress-2022.3599","is_oa":false,"landing_page_url":"https://doi.org/10.1183/13993003.congress-2022.3599","pdf_url":null,"source":{"id":"https://openalex.org/S4210207896","display_name":"European Respiratory Journal","issn_l":"0903-1936","issn":["0903-1936","1399-3003"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310317833","host_organization_name":"European Respiratory Society","host_organization_lineage":["https://openalex.org/P4310317833"],"host_organization_lineage_names":["European Respiratory Society"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"05.01 - Airway pharmacology and treatment","raw_type":"proceedings-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5050993599","display_name":"Andrew G. Veale","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210095029","display_name":"NZ Respiratory & Sleep Institute","ror":"https://ror.org/00t9eqw18","country_code":"NZ","type":"healthcare","lineage":["https://openalex.org/I4210095029"]}],"countries":["NZ"],"is_corresponding":false,"raw_author_name":"A Veale","raw_affiliation_strings":["New Zealand Respiratory and Sleep Institute, Auckland, New Zealand"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"New Zealand Respiratory and Sleep Institute, Auckland, New Zealand","institution_ids":["https://openalex.org/I4210095029"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046811086","display_name":"Hiba Farah","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"H Farah","raw_affiliation_strings":["Hannibal Clinic, Hannibal, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hannibal Clinic, Hannibal, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058559018","display_name":"Ravi Mahadeva","orcid":"https://orcid.org/0000-0001-6111-5555","observed_orcids":["https://orcid.org/0000-0001-6111-5555"]},"institutions":[{"id":"https://openalex.org/I241749","display_name":"University of Cambridge","ror":"https://ror.org/013meh722","country_code":"GB","type":"education","lineage":["https://openalex.org/I241749"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"R Mahadeva","raw_affiliation_strings":["University of Cambridge, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Cambridge, Cambridge, United Kingdom","institution_ids":["https://openalex.org/I241749"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058201601","display_name":"Matt R. Baker","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M Baker","raw_affiliation_strings":["New Zealand, Auckland, New Zealand"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"New Zealand, Auckland, New Zealand","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5136427440","display_name":"B T Kuhn","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I84218800","display_name":"University of California, Davis","ror":"https://ror.org/05rrcem69","country_code":"US","type":"education","lineage":["https://openalex.org/I84218800"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"B Kuhn","raw_affiliation_strings":["UC Davis School of Medicine, Sacramento, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UC Davis School of Medicine, Sacramento, USA","institution_ids":["https://openalex.org/I84218800"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015662812","display_name":"A. Cole","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210126461","display_name":"Christchurch Clinical Studies Trust","ror":"https://ror.org/02wccra50","country_code":"NZ","type":"facility","lineage":["https://openalex.org/I4210126461","https://openalex.org/I4405259085"]}],"countries":["NZ"],"is_corresponding":false,"raw_author_name":"A Cole","raw_affiliation_strings":["Christchurch Clinical Studies Trust, Christchurch, New Zealand"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Christchurch Clinical Studies Trust, Christchurch, New Zealand","institution_ids":["https://openalex.org/I4210126461"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050889291","display_name":"C Chang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2801645848","display_name":"Waikato Hospital","ror":"https://ror.org/002zf4a56","country_code":"NZ","type":"healthcare","lineage":["https://openalex.org/I2801645848","https://openalex.org/I4405259026"]}],"countries":["NZ"],"is_corresponding":false,"raw_author_name":"C Chang","raw_affiliation_strings":["Waikato Hospital Department of Respiratory Medicine, Hamilton, New Zealand"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Waikato Hospital Department of Respiratory Medicine, Hamilton, New Zealand","institution_ids":["https://openalex.org/I2801645848"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008856093","display_name":"Cynthia D. Brown","orcid":"https://orcid.org/0000-0003-4057-0561","observed_orcids":["https://orcid.org/0000-0003-4057-0561"]},"institutions":[{"id":"https://openalex.org/I4388446366","display_name":"Indiana University Indianapolis","ror":"https://ror.org/03eftgw80","country_code":"US","type":"education","lineage":["https://openalex.org/I4388446366","https://openalex.org/I592451"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"C Brown","raw_affiliation_strings":["Indiana University, Indianapolis, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Indiana University, Indianapolis, USA","institution_ids":["https://openalex.org/I4388446366"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069872455","display_name":"M Campos","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I145608581","display_name":"University of Miami","ror":"https://ror.org/02dgjyy92","country_code":"US","type":"education","lineage":["https://openalex.org/I145608581"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"M Campos","raw_affiliation_strings":["University of Miami, Miami, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Miami, Miami, USA","institution_ids":["https://openalex.org/I145608581"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004637134","display_name":"James L. Kalabus","orcid":"https://orcid.org/0000-0001-7582-8601","observed_orcids":["https://orcid.org/0000-0001-7582-8601"]},"institutions":[{"id":"https://openalex.org/I4210126924","display_name":"Inhibrx (United States)","ror":"https://ror.org/02pr1pc58","country_code":"US","type":"company","lineage":["https://openalex.org/I4210126924"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"J Kalabus","raw_affiliation_strings":["Inhibrx, La Jolla, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Inhibrx, La Jolla, USA","institution_ids":["https://openalex.org/I4210126924"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040189373","display_name":"Teresa F. Boyea","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210126924","display_name":"Inhibrx (United States)","ror":"https://ror.org/02pr1pc58","country_code":"US","type":"company","lineage":["https://openalex.org/I4210126924"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"T Boyea","raw_affiliation_strings":["Inhibrx, La Jolla, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Inhibrx, La Jolla, USA","institution_ids":["https://openalex.org/I4210126924"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038102558","display_name":"Carson Veldstra","orcid":"https://orcid.org/0009-0001-2809-0234","observed_orcids":["https://orcid.org/0009-0001-2809-0234"]},"institutions":[{"id":"https://openalex.org/I4210126924","display_name":"Inhibrx (United States)","ror":"https://ror.org/02pr1pc58","country_code":"US","type":"company","lineage":["https://openalex.org/I4210126924"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"C Veldstra","raw_affiliation_strings":["Inhibrx, La Jolla, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Inhibrx, La Jolla, USA","institution_ids":["https://openalex.org/I4210126924"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004218727","display_name":"Vasily Andrianov","orcid":"https://orcid.org/0009-0005-1895-9126","observed_orcids":["https://orcid.org/0009-0005-1895-9126"]},"institutions":[{"id":"https://openalex.org/I4210126924","display_name":"Inhibrx (United States)","ror":"https://ror.org/02pr1pc58","country_code":"US","type":"company","lineage":["https://openalex.org/I4210126924"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"V Andrianov","raw_affiliation_strings":["Inhibrx, La Jolla, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Inhibrx, La Jolla, USA","institution_ids":["https://openalex.org/I4210126924"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054775882","display_name":"S. Bhagwat","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210126924","display_name":"Inhibrx (United States)","ror":"https://ror.org/02pr1pc58","country_code":"US","type":"company","lineage":["https://openalex.org/I4210126924"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"S Bhagwat","raw_affiliation_strings":["Inhibrx, La Jolla, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Inhibrx, La Jolla, USA","institution_ids":["https://openalex.org/I4210126924"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064638988","display_name":"Brendan P. Eckelman","orcid":"https://orcid.org/0009-0006-7090-2642","observed_orcids":["https://orcid.org/0009-0006-7090-2642"]},"institutions":[{"id":"https://openalex.org/I4210126924","display_name":"Inhibrx (United States)","ror":"https://ror.org/02pr1pc58","country_code":"US","type":"company","lineage":["https://openalex.org/I4210126924"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"B P Eckelman","raw_affiliation_strings":["Inhibrx, La Jolla, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Inhibrx, La Jolla, USA","institution_ids":["https://openalex.org/I4210126924"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030261909","display_name":"J Loscano","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2800717037","display_name":"University of Florida Health","ror":"https://ror.org/04tk2gy88","country_code":"US","type":"education","lineage":["https://openalex.org/I2800717037","https://openalex.org/I33213144"]},{"id":"https://openalex.org/I33213144","display_name":"University of Florida","ror":"https://ror.org/02y3ad647","country_code":"US","type":"education","lineage":["https://openalex.org/I33213144"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"J Loscano","raw_affiliation_strings":["University of Florida College of Medicine, Gainesville, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Florida College of Medicine, Gainesville, USA","institution_ids":["https://openalex.org/I2800717037","https://openalex.org/I33213144"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5022549865","display_name":"ML Brantly","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2800717037","display_name":"University of Florida Health","ror":"https://ror.org/04tk2gy88","country_code":"US","type":"education","lineage":["https://openalex.org/I2800717037","https://openalex.org/I33213144"]},{"id":"https://openalex.org/I33213144","display_name":"University of Florida","ror":"https://ror.org/02y3ad647","country_code":"US","type":"education","lineage":["https://openalex.org/I33213144"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"M Brantly","raw_affiliation_strings":["University of Florida College of Medicine, Gainesville, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Florida College of Medicine, Gainesville, USA","institution_ids":["https://openalex.org/I2800717037","https://openalex.org/I33213144"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":10,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":"3599","last_page":"3599"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10143","display_name":"Chronic Obstructive Pulmonary Disease (COPD) Research","score":0.33889999985694885,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10143","display_name":"Chronic Obstructive Pulmonary Disease (COPD) Research","score":0.33889999985694885,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.11219999939203262,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11124","display_name":"Protein purification and stability","score":0.08569999784231186,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/alpha-1-antitrypsin-deficiency","display_name":"alpha-1 antitrypsin deficiency","score":0.9739999771118164},{"id":"https://openalex.org/keywords/alpha-1-antitrypsin","display_name":"alpha-1-antitrypsin","score":0.8050000071525574},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8040000200271606},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.9369999766349792},{"id":"https://openalex.org/keywords/immunogenicity","display_name":"immunogenicity","score":0.8740000128746033},{"id":"https://openalex.org/keywords/safety","display_name":"safety","score":0.6850000023841858},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.5120000243186951},{"id":"https://openalex.org/keywords/emphysema","display_name":"emphysema","score":0.6269999742507935},{"id":"https://openalex.org/keywords/lung-function","display_name":"lung function","score":0.5709999799728394}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7498127818107605},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.7413886785507202},{"id":"https://openalex.org/C2780868878","wikidata":"https://www.wikidata.org/wiki/Q1660197","display_name":"Immunogenicity","level":3,"score":0.6673649549484253},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.6477329730987549},{"id":"https://openalex.org/C40767141","wikidata":"https://www.wikidata.org/wiki/Q285697","display_name":"Recombinant DNA","level":3,"score":0.5678560733795166},{"id":"https://openalex.org/C123894998","wikidata":"https://www.wikidata.org/wiki/Q425158","display_name":"Fusion protein","level":4,"score":0.5346324443817139},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.43034207820892334},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.41499099135398865},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.37596821784973145},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.35611552000045776},{"id":"https://openalex.org/C147483822","wikidata":"https://www.wikidata.org/wiki/Q103537","display_name":"Antigen","level":2,"score":0.29880499839782715},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.15579771995544434},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0952533483505249},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1183/13993003.congress-2022.3599","doi":"https://doi.org/10.1183/13993003.congress-2022.3599","is_oa":false,"landing_page_url":"https://doi.org/10.1183/13993003.congress-2022.3599","pdf_url":null,"source":{"id":"https://openalex.org/S4210207896","display_name":"European Respiratory Journal","issn_l":"0903-1936","issn":["0903-1936","1399-3003"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310317833","host_organization_name":"European Respiratory Society","host_organization_lineage":["https://openalex.org/P4310317833"],"host_organization_lineage_names":["European Respiratory Society"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"05.01 - Airway pharmacology and treatment","raw_type":"proceedings-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4399110210","https://openalex.org/W4293244032","https://openalex.org/W4367609345","https://openalex.org/W4225326846","https://openalex.org/W7161540247","https://openalex.org/W3187853065","https://openalex.org/W3130008458","https://openalex.org/W2906081508","https://openalex.org/W2097516276","https://openalex.org/W4396507070"],"abstract_inverted_index":{"AATD":[0,84,108,153],"is":[1,24,68],"a":[2],"genetic":[3],"disorder":[4],"characterized":[5],"by":[6,196],"low":[7],"levels":[8,54,148,173,189,205],"of":[9,14,81,92,104,170,179,190],"AAT":[10,21,53,147,172,192,203],"causing":[11],"emphysema,":[12],"loss":[13],"lung":[15],"function,":[16],"and":[17,51,79,124,145],"decreased":[18],"survival.":[19],"Plasma-derived":[20],"(pdAAT)":[22],"therapy":[23],"approved":[25],"in":[26,151,157],"many":[27],"countries":[28],"but":[29],"access":[30],"ex-US":[31],"remains":[32],"limited":[33],"due":[34],"to":[35,48,75],"cost/supply.":[36],"Here":[37],"we":[38],"describe":[39],"the":[40,56],"recombinant":[41],"human":[42],"AAT-Fc":[43],"fusion":[44],"protein,":[45],"INBRX-101,":[46],"designed":[47,74],"safely":[49],"achieve":[50],"maintain":[52],"within":[55],"normal":[57,202],"range":[58],"(>20":[59,206],"\u00b5M)":[60,207],"using":[61],"every":[62,185,209],"3":[63,186],"wk":[64],"dosing.":[65],"This":[66],"study":[67],"an":[69],"open-label,":[70],"international":[71],"Phase":[72],"1":[73],"assess":[76],"safety,":[77],"PK/PD,":[78],"immunogenicity":[80],"INBRX-101":[82,99,113,128,158,200],"(NCT03815396).":[83],"patients":[85,109],"were":[86,149,160],"administered":[87],"single":[88],"or":[89,96,137,182],"multiple":[90,177],"doses":[91,178],"10,":[93],"40,":[94],"80":[95,121,183],"120":[97,125],"mg/kg":[98,116,119,122,126,181,184],"via":[100],"IV":[101],"infusion.":[102],"As":[103],"November":[105],"2021,":[106],"24":[107],"have":[110],"been":[111,130],"dosed":[112],"at":[114],"10":[115],"(n=6),":[117,120],"40":[118,180],"(n=6)":[123],"(n=6).":[127],"has":[129],"well":[131],"tolerated":[132],"without":[133],"serious":[134],"adverse":[135,140],"reactions":[136],"severe":[138],"drug-related":[139],"events.":[141],"Serum":[142],"antigenic":[143],"PK":[144],"functional":[146,171,191],"assessed":[150],"21":[152],"patients.":[154],"Dose-dependent":[155],"increases":[156],"exposure":[159],"observed.":[161],"Terminal":[162],"half-life":[163],"was":[164,174],"15":[165],"\u2013":[166],"19":[167],"days.":[168],"Accumulation":[169],"observed":[175],"following":[176],"wks.":[187],"Trough":[188],"exceeded":[193],"those":[194],"achieved":[195],"current":[197],"pdAAT":[198],"therapies.":[199],"maintains":[201],"serum":[204],"with":[208,212],"3-wk":[210],"dosing,":[211],"potential":[213],"for":[214],"longer":[215],"intervals.":[216]},"counts_by_year":[{"year":2024,"cited_by_count":2}],"updated_date":"2026-11-01T11:40:01.658920","created_date":"2023-01-06T00:00:00"}